Summary of SMC product assessment decisions

The Scottish Medicines Consortium (SMC) has announced its decision on the following therapies:

 Accepted for use
  • Formoterol Easyhaler for asthma and COPD.
  • Lucentis (ranibizumab) for wet AMD.
  • Neupro (rotigotine) patches for early PD.
  • Prezista (darunavir) for adult HIV patients.
  • Symbicort SMART (budesonide + formoterol) for adults with asthma.

Accepted for restricted use, conditions apply:

  • Byetta (exenatide) for type 2 diabetes with metformin and/or sulphonylureas.
  • Medikinet XL (methylphenidate) for ADHD.
  • Noxafil (posaconazole) for prophylaxis of invasive fungal infections in immunocompromised patients.
  • Emselex (darifenacin) for overactive bladder syndrome.
  • Singulair Paediatric (montelukast) for children aged 2—14 years with mild persistent asthma.
 Rejected for use
  • Aldara (imiquimod) for actinic keratoses. 
  • Sutent (sunitinib) for advanced and/or metastatic renal cell carcinoma. 
  • Tarceva (erlotinib) for metastatic pancreatic cancer.
  • Zevalin (ibritumomab) for follicular B-cell non-Hodgkin’s lymphoma.
  • Zibor (bemiparin) for all indications.
  • Avastin (bevacizumab) with paclitaxel for metastatic breast cancer.
  • Herceptin (trastuzumab) with an aromatase inhibitor for metastatic breast cancer.

Further information:

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us: